 <h1>Kisqali Femara Co-Pack Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>letrozole / ribociclib</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about letrozole / ribociclib. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Kisqali Femara Co-Pack.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to letrozole/ribociclib: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, letrozole / ribociclib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking letrozole / ribociclib:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bladder pain</li>
<li>bleeding gums</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>bloody or cloudy urine</li>
<li>chills</li>
<li>cough</li>
<li>decrease in height</li>
<li>difficult, burning, or painful urination</li>
<li>fever</li>
<li>frequent urge to urinate</li>
<li>lower back or side pain</li>
<li>pain in the back, ribs, arms, or legs</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>sore throat</li>
<li>tightness in the chest</li>
<li>tingling of the hands or feet</li>
<li>trouble breathing</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Chest pain</li>
<li>confusion</li>
<li>dark urine</li>
<li>fainting</li>
<li>general feeling of discomfort or illness</li>
<li>irregular heartbeat</li>
<li>loss of appetite</li>
<li>mood or mental changes</li>
<li>muscle cramps in the hands, arms, feet, legs, or face</li>
<li>nausea</li>
<li>numbness and tingling around the mouth, fingertips, or feet</li>
<li>pain or tenderness in the upper stomach</li>
<li>pale stools</li>
<li>seizures</li>
<li>stomach cramps</li>
<li>thickening of bronchial secretions</li>
<li>tremor</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, loosening of skin</li>
<li>diarrhea</li>
<li>joint or muscle pain</li>
<li>rash or itching skin</li>
<li>red irritated eyes</li>
<li>red skin lesions, often with a purple center</li>
<li>swollen glands</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of letrozole / ribociclib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>constipation</li>
<li>dry skin</li>
<li>hair loss or thinning</li>
<li>headache</li>
<li>lack or loss of strength</li>
<li>mouth or throat pain</li>
<li>swelling or inflammation of the mouth</li>
<li>trouble sleeping</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Belching</li>
<li>dry eye</li>
<li>heartburn</li>
<li>increased tearing</li>
<li>indigestion</li>
<li>patchy loss of skin color</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to letrozole / ribociclib: oral tablet</i></p><h3>General</h3><p>The most common adverse reactions and laboratory abnormalities (20% or more frequency) were decreased leukocyte count (93%), decreased neutrophil count (93%), neutropenia (75%), decreased hemoglobin count (57%), nausea (52%), decreased lymphocyte count (51%), increased ALT (46%), increased AST (44%), fatigue (37%), diarrhea (35%), alopecia (33%), leukopenia (33%), decreased platelet count (29%), vomiting (29%), constipation (25%), headache (22%), back pain (20%), and increased creatinine (20%).<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Decreased leukocyte count (93%), decreased neutrophil count (93%), neutropenia (75%), decreased hemoglobin count (57%), decreased lymphocyte count (51%), leukopenia (33%), decreased platelet count (29%), anemia (18%), lymphopenia (11%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (52%), diarrhea (35%), vomiting (29%), constipation (25%), stomatitis (12%), abdominal pain (11%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased ALT (46%), increased AST (44%), abnormal liver function tests (18%)</p>
<p><b>Frequency not reported</b>: Increased blood bilirubin<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (37%), pyrexia (13%), peripheral edema (12%)</p>
<p><b>Uncommon</b> (0.1% to 1%): On-treatment death<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (33%), rash (17%), pruritus (14%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (22%)</p>
<p><b>Common</b> (1% to 10%): Syncope<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (33%), back pain (20%)</p>
<p><b>Common</b> (1% to 10%): Fractures</p>
<p><b>Uncommon</b> (0.1% to 1%): Osteoporosis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (20%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (19%), decreased phosphorus (13%), decreased potassium (11%)</p>
<p><b>Frequency not reported</b>: Hypokalemia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (12%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (12%)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (11%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): QT interval prolongation<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Kisqali Femara Co-Pack (letrozole-ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Kisqali Femara Co-Pack (letrozole / ribociclib)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>Drug class: antineoplastic combinations</li>
<li>FDA Alerts (1)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Kisqali Femara Co-Pack 400 mg-2.5 mg Dose</li>
<li>Kisqali Femara Co-Pack 600 mg-2.5 mg Dose</li>
<li>Kisqali Femara Co-Pack &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Breast Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to letrozole / ribociclib: oral tablet</i></p><h3>General</h3><p>The most common adverse reactions and laboratory abnormalities (20% or more frequency) were decreased leukocyte count (93%), decreased neutrophil count (93%), neutropenia (75%), decreased hemoglobin count (57%), nausea (52%), decreased lymphocyte count (51%), increased ALT (46%), increased AST (44%), fatigue (37%), diarrhea (35%), alopecia (33%), leukopenia (33%), decreased platelet count (29%), vomiting (29%), constipation (25%), headache (22%), back pain (20%), and increased creatinine (20%).<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Decreased leukocyte count (93%), decreased neutrophil count (93%), neutropenia (75%), decreased hemoglobin count (57%), decreased lymphocyte count (51%), leukopenia (33%), decreased platelet count (29%), anemia (18%), lymphopenia (11%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (52%), diarrhea (35%), vomiting (29%), constipation (25%), stomatitis (12%), abdominal pain (11%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased ALT (46%), increased AST (44%), abnormal liver function tests (18%)</p><p><b>Frequency not reported</b>: Increased blood bilirubin<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (37%), pyrexia (13%), peripheral edema (12%)</p><p><b>Uncommon</b> (0.1% to 1%): On-treatment death<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (33%), rash (17%), pruritus (14%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (22%)</p><p><b>Common</b> (1% to 10%): Syncope<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (33%), back pain (20%)</p><p><b>Common</b> (1% to 10%): Fractures</p><p><b>Uncommon</b> (0.1% to 1%): Osteoporosis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (20%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (19%), decreased phosphorus (13%), decreased potassium (11%)</p><p><b>Frequency not reported</b>: Hypokalemia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (12%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (12%)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (11%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): QT interval prolongation<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Kisqali Femara Co-Pack (letrozole-ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ. </p><h2>More about Kisqali Femara Co-Pack (letrozole / ribociclib)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>Drug class: antineoplastic combinations</li>
<li>FDA Alerts (1)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Kisqali Femara Co-Pack 400 mg-2.5 mg Dose</li>
<li>Kisqali Femara Co-Pack 600 mg-2.5 mg Dose</li>
<li>Kisqali Femara Co-Pack &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Breast Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>